Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population

Milena M. McLaughlin*, Audrey Galal, Chad L. Richardson, Sarah H. Sutton, Viktorija O. Barr, Niketa Patel, Porntiwa Mitchell, Valentina Stosor

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Kidney transplant recipients who are switched to atovaquone (ATO) from trimethoprim-sulfamethoxazole (TMP/SMX) for Pneumocystis jirovecii pneumonia (PJP) prophylaxis because of adverse events or complications may miss opportunities to be re-challenged with TMP/SMX, the first-line agent. This single-site, retrospective study assessed kidney transplant recipients for documented reasons for switching from TMP/SMX to alternate PJP prophylaxis and outcomes of TMP/SMX re-challenge. Out of 166 patients, 155 initially received TMP/SMX; of these, 31 were switched to ATO for various reasons. Fourteen patients receiving ATO were re-challenged with TMP/SMX; all were successfully re-initiated on TMP/SMX therapy. Most patients switched to ATO post kidney transplant secondary to non-hypersensitivity reasons should be re-challenged with TMP/SMX because of the advantages it provides over other agents.

Original languageEnglish (US)
Article numbere12769
JournalTransplant Infectious Disease
Volume19
Issue number6
DOIs
StatePublished - Dec 2017

Keywords

  • Pneumocystis jirovecii pneumonia (PJP)
  • atovaquone
  • kidney transplant
  • prophylaxis
  • trimethoprim-sulfamethoxazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Transplantation

Fingerprint Dive into the research topics of 'Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population'. Together they form a unique fingerprint.

  • Cite this